Advertisement

Topics

Latest "Onxeo S.A." News Stories

12:38 EST 18th December 2018 | BioPortfolio

Here are the most relevant search results for "Onxeo S.A." found in our extensive news archives from over 250 global news sources.

More Information about Onxeo S.A. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Onxeo S.A. for you to read. Along with our medical data and news we also list Onxeo S.A. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Onxeo S.A. Companies for you to search.

Showing "Onxeo" News Articles, all 20

Thursday 13th December 2018

Onxeo Reports Decision from the Paris Court of Appeal in the Lawsuit against SpeBio/SpePharm

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA D...


Monday 3rd December 2018

Onxeo: Summary of the End of the Liquidity Contract with CM-CIC Securities and Implementation of a New Liquidity Contract with Kepler Cheuvreux

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA D...

Tuesday 27th November 2018

Onxeo (ONXEO) - Green light for Ph Ib/II after DRIIV-1 interim data

Edison Investment Research - Pharmaceutical & healthcare - Onxeo: Onxeo’s lead asset, AsiDNA, is currently being tested in a Phase I DRIIV-1 trial in patients with advanced solid tumours (n=36). Interim results were announced recently, based on which Onxeo will initiate a further Phase Ib/II development programme, likely combining AsiDNA with other standard-of-care drugs that have shown the ...


Friday 9th November 2018

Onxeo SA ONXEO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryOnxeo SA Onxeo is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as livatag, belchop, beleodaq, amep, asidna and validive, among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer, among o...

Monday 5th November 2018

DNA Repair Treatment Shows Early Promise for Treating Cancer

Paris-based Onxeo has proved in humans the potential of a cancer treatment that interferes with DNA repair mechanisms. The therapy has potential to work in a wide range of tumors without cancer cells becoming resistant.   Onxeo has reported preliminary ... The post DNA Repair Treatment Shows Early Promise for Treating Cancer appeared first on Labiotech.eu.

Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNATM, a First-In-Class DNA Damage Response Inhibitor

Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with no drug-related serious adverse event and no dose-limiting toxicity Company intends to expand AsiDNA™ clinical program in combination in targeted indicatio...

Thursday 18th October 2018

Onxeo to Present Overview of AsiDNA for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeti...

Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced that the Company was invited to present an overview of AsiDNA™ for the ...

Sunday 14th October 2018

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January20...

Monday 1st October 2018

Onxeo SA ONXEO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryOnxeo SA Onxeo is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as livatag, belchop, beleodaq, amep, asidna and validive, among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer, among o...

Thursday 13th September 2018

Onxeo to Attend Key Investor and Partnering Conferences in the Coming Months

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, today a...

Tuesday 14th August 2018

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 31052018] Prices from USD $350

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January20...

Friday 3rd August 2018

Onxeo: Publication of the 2018 Half-Yearly Financial Report

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in part...

Monday 30th July 2018

Onxeo SA ONXEO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09052018] Prices from USD $250

SummaryOnxeo SA Onxeo is a biopharmaceutical company that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company's pipeline products include livatag, belchop, beleodaq, amep, asidna, validive, and others. It provides drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer. Onxeo's livat...

Friday 27th July 2018

Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook

Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan Preliminary safety and activity results of DRIIV-1 study are expected in Q4 2018 Two combination clinical trials with AsiDNA™ planned for early 2019 Ne...

Thursday 12th July 2018

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors

AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PARP inhibitors AsiDNA™ combined with olaparib inhibited tumor growth in an in vivo model of ovarian cancer resistant to olaparib AsiDNA...

Wednesday 11th July 2018

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to ...

Read more...

Friday 6th July 2018

Summary of Onxeo's Liquidity Contract with CM-CIC Securities

Regulatory News: Pursuant to the liquidity contract granted to CM-CIC SECURITIES regarding Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) shares, the following resources were listed in the liquidity accou...

Thursday 21st June 2018

Deals and M&As this week: Alliance Pharma, Bayer, Onxeo

Alliance Pharma plans to acquire exclusive distribution rights to Nizoral, an anti-dandruff brand, from Janssen Pharmaceutica NV for £60m ($79.5m). Alliance...Read More... The post Deals and M&As this week: Alliance Pharma, Bayer, Onxeo appeared first on Pharmaceutical Technology.

Friday 15th June 2018

Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA

Cash for Operations Extended to Q3 2020 Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the initiation of an equity financin...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks